Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Apr 06, 2022 12:30pm
100 Views
Post# 34580979

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:So anything good coming out soon

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:So anything good coming out soon

Our views were heard last year and they acceded about half what we wanted -got a financial type with some Canadian and US market experience, but part of the Canadian business club. I would hope the current Board would not allow extraneous fixed cost employees to enter the company unless and until the prospects for oncology are much clearer around the potential future financial rewards.  The IR rebrand has been ok, but without dedicated experienced IR its dormant.  Let's see who they get.  They likely need oncology success to get someone good. 

I am still guessing the Board will shrink down some, let s see.  But everyone here should formulate the questions they want answered at next weeks call and submit them.  I always submit a few and I think you would do yourself a good service to put the hard  questions to management instead of just up here . If you put it professionally and accurately to them, they should read it.  There's a lot of issues around strategy they should answer.  It can help to specify who you want to address your question to.

 


Biobob wrote: Can we mandate Wino to lobby our interest to the C suite.... I meen hiring a cheif of staff and still no IR replacement.. Jesus.. how dumb can you be.

 

<< Previous
Bullboard Posts
Next >>